Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5408862 | 0.90 | ALDH1A1 (0.50) | OPRM1OPRK1MEN1KMT2ASIGMAR1 | |
| SCHEMBL5409581 | 0.86 | CXCR3 (0.41) | OPRM1OPRK1MEN1KMT2ASIGMAR1 | |
| SCHEMBL5394580 | 0.86 | FUCA1 (0.46) | OPRM1OPRK1ALDH1A1CHRM2CHRM3 | |
| SCHEMBL5403122 | 0.84 | DRD2 (0.46) | OPRM1OPRK1CXCR3CHRM2CHRM3 | |
| SCHEMBL5417261 | 0.83 | OPRL1 (0.44) | OPRM1OPRK1KMT2ASIGMAR1 | |
| SCHEMBL5396301 | 0.81 | OPRM1 (0.44) | OPRM1OPRK1MEN1KMT2A | |
| SCHEMBL5406260 | 0.81 | CXCR3 (0.42) | SIGMAR1ALDH1A1CXCR3 | |
| SCHEMBL5403262 | 0.81 | KDM4E (0.46) | OPRM1OPRK1ALDH1A1CHRM2CHRM3 | |
| SCHEMBL5398078 | 0.79 | OPRM1 (0.42) | OPRM1OPRK1MEN1KMT2ASIGMAR1 | |
| SCHEMBL5407157 | 0.78 | OPRM1 (0.47) | OPRM1OPRK1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241887-B2 | 3-azabicyclo[3.2.1]octane derivatives | PFIZER INC (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1615894-A2 | 3-AZABICYCLO 3.2.1 OCTANE DERIVATIVES | Pfizer Products Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20040259859-A1 | 3-Azabicyclo[3.2.1]octane derivatives | PFIZER INC | 2004-12-23 | — | — | US | disclosed |
| WO-2004089908-A2 | 3-AZABICYCLO[3.2.1]OCTANE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259859-A1 | 3-Azabicyclo[3.2.1]octane derivatives | OPRD1, OPRK1, OPRM1 | OPRM1 3/4885OPRK1 2/4885MEN1 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.